1. Home
  2. ATOS vs ALOT Comparison

ATOS vs ALOT Comparison

Compare ATOS & ALOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATOS
  • ALOT
  • Stock Information
  • Founded
  • ATOS 2009
  • ALOT 1969
  • Country
  • ATOS United States
  • ALOT United States
  • Employees
  • ATOS N/A
  • ALOT N/A
  • Industry
  • ATOS Biotechnology: Pharmaceutical Preparations
  • ALOT Computer peripheral equipment
  • Sector
  • ATOS Health Care
  • ALOT Technology
  • Exchange
  • ATOS Nasdaq
  • ALOT Nasdaq
  • Market Cap
  • ATOS 140.9M
  • ALOT 114.8M
  • IPO Year
  • ATOS 2012
  • ALOT N/A
  • Fundamental
  • Price
  • ATOS $0.96
  • ALOT $13.07
  • Analyst Decision
  • ATOS Strong Buy
  • ALOT
  • Analyst Count
  • ATOS 3
  • ALOT 0
  • Target Price
  • ATOS $7.00
  • ALOT N/A
  • AVG Volume (30 Days)
  • ATOS 952.6K
  • ALOT 33.7K
  • Earning Date
  • ATOS 11-12-2024
  • ALOT 12-12-2024
  • Dividend Yield
  • ATOS N/A
  • ALOT N/A
  • EPS Growth
  • ATOS N/A
  • ALOT 12.82
  • EPS
  • ATOS N/A
  • ALOT 0.51
  • Revenue
  • ATOS N/A
  • ALOT $153,515,000.00
  • Revenue This Year
  • ATOS N/A
  • ALOT N/A
  • Revenue Next Year
  • ATOS N/A
  • ALOT N/A
  • P/E Ratio
  • ATOS N/A
  • ALOT $25.81
  • Revenue Growth
  • ATOS N/A
  • ALOT 3.48
  • 52 Week Low
  • ATOS $0.73
  • ALOT $11.83
  • 52 Week High
  • ATOS $2.31
  • ALOT $18.83
  • Technical
  • Relative Strength Index (RSI)
  • ATOS 24.57
  • ALOT 34.84
  • Support Level
  • ATOS $1.17
  • ALOT $13.30
  • Resistance Level
  • ATOS $1.30
  • ALOT $17.24
  • Average True Range (ATR)
  • ATOS 0.08
  • ALOT 0.76
  • MACD
  • ATOS -0.02
  • ALOT -0.36
  • Stochastic Oscillator
  • ATOS 1.09
  • ALOT 6.08

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

About ALOT AstroNova Inc.

AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.

Share on Social Networks: